［1］Siegel R,Ma Jiemin,Zou Zhaohui,et al.Cancer statistics,2014［J］.CA Cancer J Clin,2014,64(1):9-29.
［2］Han JY，Park K，Kim SW，et al． First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung［J］． J Clin Oncol，2012，30(10):1122-1128．
［3］Lee MH，Kong DS，Seol HJ，et al． The influence of biomarker mutations and systemic treatment on cerebral metastases from NSCLC treated with radiosurgery［J］． J Korean Neurosurg Soc，2017，60(1):21-29．
［4］Grimmig T,Matthes N,Hoeland K,et al.TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer［J］.Int J Oncol,2015,47(3):857-866.
［5］Chen C,Chen Z,Chen D,et al.Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer［J］.J Int Med Res,2015,43(2):180-187.
［6］Ding ZC,Lu X,Yu M,et al.Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis［J］.Clin Lab,2015,61(10):1343-1351.
［7］Wang Q,Yang L,Xu F,et al.Changes of lymphocyte subgroups in non-small cell lung cancer patients before and during chemotherapy［J］.Clin Lab,2015,61(10):1343-1351.
［8］Sun Weihong,Wei Xiaofang,Zhao Peng，et al.Changes in Treg cells and their cytokine production in the peripheral blood of gastric cancer patients following immunotherapy with DC-CIK cells ［J］．Chinese Journal of Cancer Biotherapy,2015,22(1):79-83.［孙伟红，魏晓芳，赵鹏，等.胃癌患者DC-CIK治疗前后外周血Treg细胞及相关细胞因子的变化［J］.中国肿瘤生物治疗杂志,2015,22(1):79-83.］
［9］Zheng C，Yu G，Wang H，et al． Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer ［J］． Int J Clin Exp Med，2015，8(8):14527-1437.
［10］Wright SE,Rewers-Felkins KA,Quinlin IS,et al.Cytotoxic T-lymphocyte immunotherapy for ovarian cancer:A pilot study［J］.Journal of Immunotherapy,2012,35(2):196-204.
［11］Kuderer NM,Dale DC,Crawford J,et al.Mortality,morbidity and cost associated with febrile neutropenia in adult cancer patients［J］.Cancer,2006,106(10):2258-2266.
［12］Fontanella C,Bolzonello S,Lederer B,et al.Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia［J］.Breast Care,2014,9(4):239-245.
［13］Cao Haiwu,Zhao Xiaohong,Lu Shiyun,et al.Relationship between development of an infection after chemotherapy and immune function and intestinal microecology in patients with a hematologic malignancy［J］.Journal of Pathogen Biology,2017,12(05):456-459.［曹海武，赵晓红，陆时运，等.恶性血液病患者化疗后并发感染与机体免疫功能及肠道微生态的关系 ［J］.中国病原生物学杂志,2017,12(05):456-459.］
［14］Mackall CL,Fleisher TA,Brown MR,et al.Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy［J］.Blood,1997,89(10):3700-3707.
［15］Chovanec M,Cierna Z,Miskovska V,et al.Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors［J］.Oncotarget,2017,8 (13):21794-21805.
［16］Zhi-Chun Ding,Xiaoyun Lu,Miao Yu,et al.Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T cell responses through the PD-1/PDL1 axis［J］.Cancer Res,2014,74(13):3441-3453.
［17］Parikh F,Duluc D,Imai N,et al.Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer［J］.Cancer Res,2014,74(24):7205-7216.
［18］Mao Liwei,Wang Yang,Liao Guoqing,et al.Influence of DC-CIK on the percentage and function of CD4+CD25+ regulatory T cell in peripheral blood of gastric cancer with ascites［J］.Modern Oncology,2016,24(12):1933-1936.［毛丽伟,王阳,廖国清，等.DC-CIK对胃癌合并腹水患者外周血CD4+CD25+调节性T细胞增殖及功能的影响［J］.现代肿瘤医学 2016,24(12):1933-1936.］
［19］Adotevi O,Pere H,Ravel P,et al.A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients［J］.J Immunother,2010,33(9):991-998.
［20］Lesterhuis WJ,Haanen JB,Punt CJ.Cancer immunotherapy-revisited［J］.Nat Rev Drug Discov,2011,10(8):591-600.